This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Israel, B. F. Articles by Kenney, S. C. Search for Related Content PubMed PubMed Citation Articles by Israel, B. F. Articles by Kenney, S. C.

¹ University of North Carolina at Chapel Hill, Chapel Hill, North Carolina and ² Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Requests for reprints: Shannon C. Kenney, Lineberger Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Chapel Hill, NC 27599-7295; Phone: 919-966-1248; Fax: 919-966-8212. E-mail: shann{at}med.unc.edu

A monoclonal antibody (Rituximab) directed against the B-cell surface antigen, CD20, is increasingly used as a therapy for B-cell lymphomas. However, CD20 is expressed on all normal mature B cells and hence is not a specific tumor target. In contrast, CD70 is expressed on highly activated lymphocytes as well as on many B-cell and T-cell lymphomas but is not expressed on the great majority of B cells and T cells. In this report, we have explored the potential utility of anti-CD70 monoclonal antibodies for treatment of CD70⁺ EBV⁺ B-cell lymphomas. Using two Burkitt's lymphoma lines (Raji and Jijoye) that express surface CD70 and a CD70^– Burkitt's lymphoma line (Akata), we show that two different monoclonal antibodies directed against human CD70 allow rabbit and human complement to kill EBV⁺ B cells in a CD70-dependent manner in vitro. In the absence of complement, neither anti-CD70 antibody induced in vitro killing of CD70⁺ cell lines. Importantly, i.p. injection of anti-CD70 antibodies also inhibited the growth of CD70⁺ Burkitt's lymphoma cells in severe combined immunodeficient mice but did not inhibit the growth of CD70^– Burkitt's lymphoma cells. These results suggest that anti-CD70 antibodies may be useful for the treatment of CD70⁺ B-cell lymphomas. [Mol Cancer Ther 2005;4(12):2037–44]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/18/05; revised 9/ 7/05; accepted 9/21/05.

This article has been cited by other articles:

				J. A. McEarchern, L. M. Smith, C. F. McDonagh, K. Klussman, K. A. Gordon, C. A. Morris-Tilden, S. Duniho, M. Ryan, T. E. Boursalian, P. J. Carter, et al. Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70 Clin. Cancer Res., December 1, 2008; 14(23): 7763 - 7772. [Abstract] [Full Text] [PDF]

				J. A. McEarchern, E. Oflazoglu, L. Francisco, C. F. McDonagh, K. A. Gordon, I. Stone, K. Klussman, E. Turcott, N. van Rooijen, P. Carter, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities Blood, February 1, 2007; 109(3): 1185 - 1192. [Abstract] [Full Text] [PDF]